NVX-CoV2601 + PCV20

NVX-Medical University of Vienna-COVID-19-pneumococcal infection refers to the concomitant administration of Novavax's **NVX-CoV2601** (an Omicron-adapted recombinant spike protein nanoparticle COVID-19 vaccine) and a **20-valent pneumococcal conjugate vaccine (PCV20)**. NVX-CoV2601 utilizes a protein subunit platform with the saponin-based **Matrix-M adjuvant** to induce an immune response against the SARS-CoV-2 spike protein. PCV20 contains capsular polysaccharides from 20 different *Streptococcus pneumoniae* serotypes, each conjugated to a CRM197 carrier protein to enhance immunogenicity through T-cell dependent pathways. This specific co-administration regimen was evaluated in a Phase 4 clinical trial led by the **Medical University of Vienna** to determine if simultaneous injection in adults aged 60 and older maintains non-inferior immunogenicity and a comparable safety profile to separate administration, aiming to optimize public health vaccination strategies for respiratory infections.

Brand names

NuvaxovidPrevnar 20Prevnar20Prevnar-20

Other names

Novavax COVID-19 vaccine + 20-valent pneumococcal conjugate vaccineOmicron-adapted Novavax vaccine + PCV20